INFINITY study showed that disease recurred in 2 of 18 GC patients treated with dual blockade of PD1 and CTLA4 with a follow-up of 13.4 months (9.7–14.2 moths)[14]. This evidence concerns the gene CTLA4 and gastric cancer.